{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:13:31Z","timestamp":1792671211022,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/nrclinonc.2015.152","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T07:03:12Z","timestamp":1442905392000},"page":"92-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":250,"title":["Cancer-treatment-induced neurotoxicity\u2014focus on newer treatments"],"prefix":"10.1038","volume":"13","author":[{"given":"Jacqueline B.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"BFnrclinonc2015152_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780195366747.001.0001","volume-title":"Neurologic Complications of Cancer","author":"LM DeAngelis","year":"2008","unstructured":"DeAngelis, L. M. & Posner, J. B. Neurologic Complications of Cancer 2nd edn. (Oxford University Press, 2008)."},{"key":"BFnrclinonc2015152_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"AA Argyriou","year":"2012","unstructured":"Argyriou, A. A., Bruna, J., Marmiroli, P. & Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 82, 51\u201377 (2012).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BFnrclinonc2015152_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/0360-3016(94)00550-8","volume":"31","author":"DD Roman","year":"1995","unstructured":"Roman, D. D. & Sperduto, P. W. Neuropsychological effects of cranial radiation: current knowledge and future directions. Int. J. Radiat. Oncol. Biol. Phys. 31, 983\u2013998 (1995).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc2015152_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00280-013-2155-4","volume":"71","author":"N Letarte","year":"2013","unstructured":"Letarte, N., Bressler, L. R. & Villano, J. L. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother. Pharmacol. 71, 1561\u20131565 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2015152_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot., I., Blank, C. U., Boogerd, W. & Brandsma, D. Neurological immune-related adverse events of ipilimumab. Pract. Neurol. 13, 278\u2013280 (2013).","journal-title":"Pract. Neurol."},{"key":"BFnrclinonc2015152_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","volume":"29","author":"RS Magge","year":"2015","unstructured":"Magge, R. S. & DeAngelis, L. M. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 29, 93\u2013100 (2015).","journal-title":"Blood Rev."},{"key":"BFnrclinonc2015152_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/B978-0-7020-4088-7.00080-8","volume":"121","author":"R Soffietti","year":"2014","unstructured":"Soffietti, R., Trevisan, E. & Ruda, R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb. Clin. Neurol. 121, 1199\u20131218 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"BFnrclinonc2015152_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0733-8619(02)00034-8","volume":"21","author":"SR Plotkin","year":"2003","unstructured":"Plotkin, S. R. & Wen, P. Y. Neurologic complications of cancer therapy. Neurol. Clin. 21, 279\u2013318 (2003).","journal-title":"Neurol. Clin."},{"key":"BFnrclinonc2015152_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2008.01.033","volume":"132","author":"C Zhao","year":"2008","unstructured":"Zhao, C., Deng, W. & Gage, F. H. Mechanisms and functional implications of adult neurogenesis. Cell 132, 645\u2013660 (2008).","journal-title":"Cell"},{"key":"BFnrclinonc2015152_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fonc.2012.00073","volume":"2","author":"D Greene-Schloesser","year":"2012","unstructured":"Greene-Schloesser, D. et al. Radiation-induced brain injury: a review. Front. Oncol. 2, 73 (2012).","journal-title":"Front. Oncol."},{"key":"BFnrclinonc2015152_CR11","first-page":"343","volume":"18","author":"LR Rogers","year":"2012","unstructured":"Rogers, L. R. Neurologic complications of radiation. Continuum (Minneap. Minn.) 18, 343\u2013354 (2012).","journal-title":"Continuum (Minneap. Minn.)"},{"key":"BFnrclinonc2015152_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby, E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 31, 456\u2013473 (2005).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrclinonc2015152_CR13","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga, J. et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162\u20132171 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/A:1006341717398","volume":"18","author":"RO Dillman","year":"1999","unstructured":"Dillman, R. O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18, 465\u2013471 (1999).","journal-title":"Cancer Metastasis Rev."},{"key":"BFnrclinonc2015152_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","volume":"21","author":"MM Goldenberg","year":"1999","unstructured":"Goldenberg, M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309\u2013318 (1999).","journal-title":"Clin. Ther."},{"key":"BFnrclinonc2015152_CR16","first-page":"4223","volume":"29","author":"FG van Rooij","year":"2009","unstructured":"van Rooij, F. G., Dorresteijn, L. D., Van Bokhoven, M. M. & Verstappen, C. C. A throbbing pain in the head: trastuzumab-induced migraine. Anticancer Res. 29, 4223\u20134225 (2009).","journal-title":"Anticancer Res."},{"key":"BFnrclinonc2015152_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/02841860601009455","volume":"46","author":"P Pfeiffer","year":"2007","unstructured":"Pfeiffer, P. et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46, 697\u2013701 (2007).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc2015152_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2015152_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","volume":"99","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361\u2013371 (2014).","journal-title":"Int. J. Hematol."},{"key":"BFnrclinonc2015152_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.41.5.672","volume":"41","author":"CA Meyers","year":"1991","unstructured":"Meyers, C. A., Scheibel, R. S. & Forman, A. D. Persistent neurotoxicity of systemically administered interferon-\u03b1. Neurology 41, 672\u2013676 (1991).","journal-title":"Neurology"},{"key":"BFnrclinonc2015152_CR21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V80.5.1141.1141","volume":"80","author":"B Biesma","year":"1992","unstructured":"Biesma, B. et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80, 1141\u20131148 (1992).","journal-title":"Blood"},{"key":"BFnrclinonc2015152_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00002018-200022030-00005","volume":"22","author":"S Jolles","year":"2000","unstructured":"Jolles, S., Sewell, W. A. & Leighton, C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf. 22, 215\u2013226 (2000).","journal-title":"Drug Saf."},{"key":"BFnrclinonc2015152_CR23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","volume":"63","author":"CC Verstappen","year":"2003","unstructured":"Verstappen, C. C., Heimans, J. J., Hoekman, K. & Postma, T. J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63, 1549\u20131563 (2003).","journal-title":"Drugs"},{"key":"BFnrclinonc2015152_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/A:1015752331041","volume":"57","author":"KA Jaeckle","year":"2002","unstructured":"Jaeckle, K. A. et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 57, 231\u2013239 (2002).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc2015152_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/1097-0142(196901)23:1<122::AID-CNCR2820230114>3.0.CO;2-E","volume":"23","author":"LM Slater","year":"1969","unstructured":"Slater, L. M., Wainer, R. A. & Serpick, A. A. Vincristine neurotoxicity with hyponatremia. Cancer 23, 122\u2013125 (1969).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-008-0645-y","volume":"88","author":"YL Kwong","year":"2009","unstructured":"Kwong, Y. L., Yeung, D. Y. & Chan, J. C. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann. Hematol. 88, 193\u2013201 (2009).","journal-title":"Ann. Hematol."},{"key":"BFnrclinonc2015152_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.seminoncol.2006.03.006","volume":"33","author":"JK Sul","year":"2006","unstructured":"Sul, J. K. & Deangelis, L. M. Neurologic complications of cancer chemotherapy. Semin. Oncol. 33, 324\u2013332 (2006).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc2015152_CR28","first-page":"355","volume":"18","author":"EQ Lee","year":"2012","unstructured":"Lee, E. Q., Arrillaga-Romany, I. C. & Wen, P. Y. Neurologic complications of cancer drug therapies. Continuum (Minneap. Minn.) 18, 355\u2013365 (2012).","journal-title":"Continuum (Minneap. Minn.)"},{"key":"BFnrclinonc2015152_CR29","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017\u20134023 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2015152_CR30","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc2015152_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/bjc.1983.63","volume":"47","author":"AZ Rohatiner","year":"1983","unstructured":"Rohatiner, A. Z. et al. Central nervous system toxicity of interferon. Br. J. Cancer 47, 419\u2013422 (1983).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2015152_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00280-008-0876-6","volume":"63","author":"C Sioka","year":"2009","unstructured":"Sioka, C. & Kyritsis, A. P. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol. 63, 761\u2013767 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrclinonc2015152_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/0003-4819-107-2-293","volume":"107","author":"KD Denicoff","year":"1987","unstructured":"Denicoff, K. D. et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107, 293\u2013300 (1987).","journal-title":"Ann. Intern. Med."},{"key":"BFnrclinonc2015152_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4062\/biomolther.2012.20.4.357","volume":"20","author":"YW Lee","year":"2012","unstructured":"Lee, Y. W., Cho, H. J., Lee, W. H. & Sonntag, W. E. Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targets. Biomol. Ther. (Seoul) 20, 357\u2013370 (2012).","journal-title":"Biomol. Ther. (Seoul)"},{"key":"BFnrclinonc2015152_CR35","unstructured":"[No authors listed] Chemotherapy of metastatic colorectal cancer. Prescrire Int. 19, 219\u2013224 (2010)."},{"key":"BFnrclinonc2015152_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/104345420001700107","volume":"17","author":"J Ryan","year":"2000","unstructured":"Ryan, J. Radiation somnolence syndrome. J. Pediatr. Oncol. Nurs. 17, 50\u201353 (2000).","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"BFnrclinonc2015152_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1634\/theoncologist.2008-0130","volume":"13","author":"J Dietrich","year":"2008","unstructured":"Dietrich, J., Monje, M., Wefel, J. & Meyers, C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13, 1285\u20131295 (2008).","journal-title":"Oncologist"},{"key":"BFnrclinonc2015152_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1440-1789.2008.00945.x","volume":"29","author":"J Matsubayashi","year":"2009","unstructured":"Matsubayashi, J., Tsuchiya, K., Matsunaga, T. & Mukai, K. Methotrexate-related leukoencephalopathy without radiation therapy: distribution of brain lesions and pathological heterogeneity on two autopsy cases. Neuropathology 29, 105\u2013115 (2009).","journal-title":"Neuropathology"},{"key":"BFnrclinonc2015152_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1188\/09.CJON.413-421","volume":"13","author":"JS Myers","year":"2009","unstructured":"Myers, J. S. Chemotherapy-related cognitive impairment. Clin. J. Oncol. Nurs. 13, 413\u2013421 (2009).","journal-title":"Clin. J. Oncol. Nurs."},{"key":"BFnrclinonc2015152_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1078155209102511","volume":"15","author":"K Tipples","year":"2009","unstructured":"Tipples, K., Kolluri, R. B. & Raouf, S. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. J. Oncol. Pharm. Pract. 15, 237\u2013239 (2009).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"BFnrclinonc2015152_CR41","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1200\/JCO.2007.10.8464","volume":"25","author":"DP Waber","year":"2007","unstructured":"Waber, D. P. et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95\u201301. J. Clin. Oncol. 25, 4914\u20134921 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000354227","volume":"50","author":"JP Warrington","year":"2013","unstructured":"Warrington, J. P. et al. Whole brain radiation-induced vascular cognitive impairment: mechanisms and implications. J. Vasc. Res. 50, 445\u2013457 (2013).","journal-title":"J. Vasc. Res."},{"key":"BFnrclinonc2015152_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00019052-200304000-00002","volume":"16","author":"ML Monje","year":"2003","unstructured":"Monje, M. L. & Palmer, T. Radiation injury and neurogenesis. Curr. Opin. Neurol. 16, 129\u2013134 (2003).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrclinonc2015152_CR44","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-11-2000","volume":"18","author":"LA Christie","year":"2012","unstructured":"Christie, L. A. et al. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin. Cancer Res. 18, 1954\u20131965 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2015152_CR45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbr.2011.05.012","volume":"227","author":"M Monje","year":"2012","unstructured":"Monje, M. & Dietrich, J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav. Brain Res. 227, 376\u2013379 (2012).","journal-title":"Behav. Brain Res."},{"key":"BFnrclinonc2015152_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4419-6306-2_15","volume":"678","author":"JS Myers","year":"2010","unstructured":"Myers, J. S. The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv. Exp. Med. Biol. 678, 119\u2013123 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnrclinonc2015152_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ddrr.26","volume":"14","author":"M Monje","year":"2008","unstructured":"Monje, M. Cranial radiation therapy and damage to hippocampal neurogenesis. Dev. Disabil. Res. Rev. 14, 238\u2013242 (2008).","journal-title":"Dev. Disabil. Res. Rev."},{"key":"BFnrclinonc2015152_CR48","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1126\/science.1088417","volume":"302","author":"ML Monje","year":"2003","unstructured":"Monje, M. L., Toda, H. & Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760\u20131765 (2003).","journal-title":"Science"},{"key":"BFnrclinonc2015152_CR49","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","volume":"32","author":"V Gondi","year":"2014","unstructured":"Gondi, V. et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J. Clin. Oncol. 32, 3810\u20133816 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR50","unstructured":"Radiation Therapy Oncology Group. RTOG 0933 Protocol Information [online] , (2012)."},{"key":"BFnrclinonc2015152_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/jbiol69","volume":"7","author":"R Han","year":"2008","unstructured":"Han, R. et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J. Biol. 7, 12 (2008).","journal-title":"J. Biol."},{"key":"BFnrclinonc2015152_CR52","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1371\/journal.pone.0000588","volume":"2","author":"G Panagiotakos","year":"2007","unstructured":"Panagiotakos, G. et al. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain. PLoS ONE 2, e588 (2007).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2015152_CR53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00429-013-0683-7","volume":"220","author":"A Sierra","year":"2015","unstructured":"Sierra, A., Laitinen, T., Grohn, O. & Pitkanen, A. Diffusion tensor imaging of hippocampal network plasticity. Brain Struct. Funct. 220, 781\u2013801 (2015).","journal-title":"Brain Struct. Funct."},{"key":"BFnrclinonc2015152_CR54","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11910-007-0072-9","volume":"7","author":"JR Berger","year":"2007","unstructured":"Berger, J. R. Progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep. 7, 461\u2013469 (2007).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrclinonc2015152_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ajh.10085","volume":"70","author":"B Vidarsson","year":"2002","unstructured":"Vidarsson, B., Mosher, D. F., Salamat, M. S., Isaksson, H. J. & Onundarson, P. T. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am. J. Hematol. 70, 51\u201354 (2002).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2015152_CR56","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834\u20134840 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2015152_CR57","doi-asserted-by":"publisher","unstructured":"Isidoro, L., Pires, P., Rito, L. & Cordeiro, G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. http:\/\/dx.doi.org\/10.1136\/bcr-2013-201781 (2014).","DOI":"10.1136\/bcr-2013-201781"},{"key":"BFnrclinonc2015152_CR58","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.28712","volume":"120","author":"KR Carson","year":"2014","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120, 2464\u20132471 (2014).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.STR.15.3.413","volume":"15","author":"S Strandgaard","year":"1984","unstructured":"Strandgaard, S. & Paulson, O. B. Cerebral autoregulation. Stroke 15, 413\u2013416 (1984).","journal-title":"Stroke"},{"key":"BFnrclinonc2015152_CR60","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(03)13177-7","volume":"361","author":"MD Savvidou","year":"2003","unstructured":"Savvidou, M. D. et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361, 1511\u20131517 (2003).","journal-title":"Lancet"},{"key":"BFnrclinonc2015152_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","volume":"82","author":"A Marra","year":"2014","unstructured":"Marra, A. et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med. Hypotheses 82, 619\u2013622 (2014).","journal-title":"Med. Hypotheses"},{"key":"BFnrclinonc2015152_CR62","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/B978-0-7020-4088-7.00109-7","volume":"121","author":"C Lamy","year":"2014","unstructured":"Lamy, C., Oppenheim, C. & Mas, J. L. Posterior reversible encephalopathy syndrome. Handb. Clin. Neurol. 121, 1687\u20131701 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"BFnrclinonc2015152_CR63","first-page":"163","volume":"5","author":"A Bhatt","year":"2009","unstructured":"Bhatt, A., Farooq, M. U., Majid, A. & Kassab, M. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat. Clin. Pract. Neurol. 5, 163\u2013169 (2009).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrclinonc2015152_CR64","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMc052954","volume":"354","author":"P Glusker","year":"2006","unstructured":"Glusker, P., Recht, L. & Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980\u2013982 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2015152_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2008.01059.x","volume":"119","author":"W Grisold","year":"2009","unstructured":"Grisold, W., Oberndorfer, S. & Struhal, W. Stroke and cancer: a review. Acta Neurol. Scand. 119, 1\u201316 (2009).","journal-title":"Acta Neurol. Scand."},{"key":"BFnrclinonc2015152_CR66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.clineuro.2005.03.008","volume":"108","author":"SH Li","year":"2006","unstructured":"Li, S. H. et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin. Neurol. Neurosurg. 108, 150\u2013156 (2006).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"BFnrclinonc2015152_CR67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1055\/s-2004-861539","volume":"24","author":"LR Rogers","year":"2004","unstructured":"Rogers, L. R. Cerebrovascular complications in patients with cancer. Semin. Neurol. 24, 453\u2013460 (2004).","journal-title":"Semin. Neurol."},{"key":"BFnrclinonc2015152_CR68","first-page":"1688","volume":"25","author":"N Rollins","year":"2004","unstructured":"Rollins, N., Winick, N., Bash, R. & Booth, T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am. J. Neuroradiol. 25, 1688\u20131695 (2004).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"BFnrclinonc2015152_CR69","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi, F. S. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632\u2013642 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"BFnrclinonc2015152_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-005-4569-2","volume":"76","author":"ME Haykin","year":"2006","unstructured":"Haykin, M. E., Gorman, M., van Hoff, J., Fulbright, R. K. & Baehring, J. M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J. Neurooncol. 76, 153\u2013157 (2006).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc2015152_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/1817-1745.66683","volume":"5","author":"NA Wani","year":"2010","unstructured":"Wani, N. A., Kosar, T., Pala, N. A. & Qureshi, U. A. Sagittal sinus thrombosis due to L-asparaginase. J. Pediatr. Neurosci. 5, 32\u201335 (2010).","journal-title":"J. Pediatr. Neurosci."},{"key":"BFnrclinonc2015152_CR72","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","volume":"22","author":"F Elice","year":"2009","unstructured":"Elice, F., Rodeghiero, F., Falanga, A. & Rickles, F. R. Thrombosis associated with angiogenesis inhibitors. Best Pract. Res. Clin. Haematol. 22, 115\u2013128 (2009).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"BFnrclinonc2015152_CR73","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-014-1571-6","volume":"120","author":"Y Odia","year":"2014","unstructured":"Odia, Y., Shih, J. H., Kreisl, T. N. & Fine, H. A. Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J. Neurooncol. 120, 431\u2013440 (2014).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc2015152_CR74","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","volume":"22","author":"FA Schutz","year":"2011","unstructured":"Schutz, F. A., Je, Y., Azzi, G. R., Nguyen, P. L. & Choueiri, T. K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann. Oncol. 22, 1404\u20131412 (2011).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2015152_CR75","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/neurosurgery\/46.1.138","volume":"46","author":"MM O'Connor","year":"2000","unstructured":"O'Connor, M. M. & Mayberg, M. R. Effects of radiation on cerebral vasculature: a review. Neurosurgery 46, 138\u2013149 (2000).","journal-title":"Neurosurgery"},{"key":"BFnrclinonc2015152_CR76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11060-014-1390-9","volume":"117","author":"A Di Giannatale","year":"2014","unstructured":"Di Giannatale, A. et al. Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy. J. Neurooncol. 117, 311\u2013320 (2014).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc2015152_CR77","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s10072-006-0521-2","volume":"26","author":"P Ferroli","year":"2006","unstructured":"Ferroli, P. et al. Cerebral cavernomas and seizures: a retrospective study on 163 patients who underwent pure lesionectomy. Neurol. Sci. 26, 390\u2013394 (2006).","journal-title":"Neurol. Sci."},{"key":"BFnrclinonc2015152_CR78","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","volume":"9","author":"WJ Baker","year":"1991","unstructured":"Baker, W. J., Royer, G. L. Jr & Weiss, R. B. Cytarabine and neurologic toxicity. J. Clin. Oncol. 9, 679\u2013693 (1991).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR79","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.1987.5.6.927","volume":"5","author":"RH Herzig","year":"1987","unstructured":"Herzig, R. H. et al. Cerebellar toxicity with high-dose cytosine arabinoside. J. Clin. Oncol. 5, 927\u2013932 (1987).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR80","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.1985.3.5.613","volume":"3","author":"LA Dworkin","year":"1985","unstructured":"Dworkin, L. A., Goldman, R. D., Zivin, L. S. & Fuchs, P. C. Cerebellar toxicity following high-dose cytosine arabinoside. J. Clin. Oncol. 3, 613\u2013616 (1985).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR81","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","volume":"25","author":"SR Land","year":"2007","unstructured":"Land, S. R. et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J. Clin. Oncol. 25, 2205\u20132211 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR82","first-page":"919","volume":"41","author":"JR DiPalma","year":"1990","unstructured":"DiPalma, J. R. Metoclopramide: a dopamine receptor antagonist. Am. Fam. Physician 41, 919\u2013924 (1990).","journal-title":"Am. Fam. Physician"},{"key":"BFnrclinonc2015152_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2009.04189.x","volume":"31","author":"AS Rao","year":"2010","unstructured":"Rao, A. S. & Camilleri, M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther. 31, 11\u201319 (2010).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrclinonc2015152_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11910-012-0258-7","volume":"12","author":"J Fink","year":"2012","unstructured":"Fink, J., Born, D. & Chamberlain, M. C. Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors. Curr. Neurol. Neurosci. Rep. 12, 276\u2013285 (2012).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrclinonc2015152_CR85","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1748-717X-6-128","volume":"6","author":"J Chen","year":"2011","unstructured":"Chen, J. et al. Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management. Radiat. Oncol. 6, 128 (2011).","journal-title":"Radiat. Oncol."},{"key":"BFnrclinonc2015152_CR86","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin, V. A. et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 79, 1487\u20131495 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc2015152_CR87","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00415-010-5892-x","volume":"258","author":"JP Kerklaan","year":"2011","unstructured":"Kerklaan, J. P. et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J. Neurol. 258, 1098\u20131104 (2011).","journal-title":"J. Neurol."},{"key":"BFnrclinonc2015152_CR88","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/RLU.0b013e3181e4db6f","volume":"35","author":"K Farid","year":"2010","unstructured":"Farid, K. et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin. Nucl. Med. 35, 583\u2013585 (2010).","journal-title":"Clin. Nucl. Med."},{"key":"BFnrclinonc2015152_CR89","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1667\/RR3329","volume":"163","author":"S Sadetzki","year":"2005","unstructured":"Sadetzki, S. et al. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat. Res. 163, 424\u2013432 (2005).","journal-title":"Radiat. Res."},{"key":"BFnrclinonc2015152_CR90","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1215\/15228517-2007-027","volume":"9","author":"A Balasubramaniam","year":"2007","unstructured":"Balasubramaniam, A. et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol. 9, 447\u2013453 (2007).","journal-title":"Neuro Oncol."},{"key":"BFnrclinonc2015152_CR91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3171\/jns.2006.105.2.325","volume":"105","author":"J Sheehan","year":"2006","unstructured":"Sheehan, J., Yen, C. P. & Steiner, L. Gamma knife surgery-induced meningioma. Report of two cases and review of the literature. J. Neurosurg. 105, 325\u2013329 (2006).","journal-title":"J. Neurosurg."},{"key":"BFnrclinonc2015152_CR92","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1002\/cncr.10500","volume":"94","author":"S Taieb","year":"2002","unstructured":"Taieb, S., Trillet-Lenoir, V., Rambaud, L., Descos, L. & Freyer, G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94, 2434\u20132440 (2002).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR93","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s003309900278","volume":"10","author":"F Calabro","year":"2000","unstructured":"Calabro, F. & Jinkins, J. R. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur. Radiol. 10, 1079\u20131084 (2000).","journal-title":"Eur. Radiol."},{"key":"BFnrclinonc2015152_CR94","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1212\/WNL.44.11.2020","volume":"44","author":"MJ Glantz","year":"1994","unstructured":"Glantz, M. J. et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44, 2020\u20132027 (1994).","journal-title":"Neurology"},{"key":"BFnrclinonc2015152_CR95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao, B., Shroff, S., Kamiya-Matsuoka, C. & Tummala, S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16, 589\u2013593 (2014).","journal-title":"Neuro Oncol."},{"key":"BFnrclinonc2015152_CR96","first-page":"1932","volume":"17","author":"BC Bowen","year":"1996","unstructured":"Bowen, B. C., Verma, A., Brandon, A. H. & Fiedler, J. A. Radiation-induced brachial plexopathy: MR and clinical findings. AJNR Am. J. Neuroradiol. 17, 1932\u20131936 (1996).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"BFnrclinonc2015152_CR97","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/WNL.31.1.45","volume":"31","author":"SH Kori","year":"1981","unstructured":"Kori, S. H., Foley, K. M. & Posner, J. B. Brachial plexus lesions in patients with cancer: 100 cases. Neurology 31, 45\u201350 (1981).","journal-title":"Neurology"},{"key":"BFnrclinonc2015152_CR98","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0167-8140(90)90057-4","volume":"18","author":"S Powell","year":"1990","unstructured":"Powell, S., Cooke, J. & Parsons, C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother. Oncol. 18, 213\u2013220 (1990).","journal-title":"Radiother. Oncol."},{"key":"BFnrclinonc2015152_CR99","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0168-5597(93)90111-2","volume":"89","author":"A Esteban","year":"1993","unstructured":"Esteban, A. & Traba, A. Fasciculation-myokymic activity and prolonged nerve conduction block. A physiopathological relationship in radiation-induced brachial plexopathy. Electroencephalogr. Clin. Neurophysiol. 89, 382\u2013391 (1993).","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"BFnrclinonc2015152_CR100","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02841860600658252","volume":"45","author":"S Johansson","year":"2006","unstructured":"Johansson, S. Radiation induced brachial plexopathies. Acta Oncol. 45, 253\u2013257 (2006).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc2015152_CR101","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/S0959-8049(02)00229-0","volume":"38","author":"G Cavaletti","year":"2002","unstructured":"Cavaletti, G. & Zanna, C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer 38, 1832\u20131837 (2002).","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 5","key":"BFnrclinonc2015152_CR102","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2009.0078","volume":"7","author":"MD Stubblefield","year":"2009","unstructured":"Stubblefield, M. D. et al. NCCN task force report: management of neuropathy in cancer. J. Natl Compr. Canc. Netw. 7 (Suppl. 5), S1\u2013S26 (2009).","journal-title":"J. Natl Compr. Canc. Netw."},{"issue":"1","key":"BFnrclinonc2015152_CR103","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nrc2167-c1","volume":"8","author":"Guido Cavaletti","year":"2008","unstructured":"Cavaletti, G. Peripheral neurotoxicity of platinum-based chemotherapy. Nat. Rev. Cancer 8, http:\/\/dx.doi.org\/10.1038\/nrc2167-c1 (2008).","journal-title":"Nature Reviews Cancer"},{"key":"BFnrclinonc2015152_CR104","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11940-010-0108-3","volume":"13","author":"G Cavaletti","year":"2011","unstructured":"Cavaletti, G., Alberti, P., Frigeni, B., Piatti, M. & Susani, E. Chemotherapy-induced neuropathy. Curr. Treat. Options Neurol. 13, 180\u2013190 (2011).","journal-title":"Curr. Treat. Options Neurol."},{"key":"BFnrclinonc2015152_CR105","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee, J. J. & Swain, S. M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24, 1633\u20131642 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR106","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park, S. B. et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 63, 419\u2013437 (2013).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc2015152_CR107","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archneur.1982.00510230045013","volume":"39","author":"TJ Walsh","year":"1982","unstructured":"Walsh, T. J., Clark, A. W., Parhad, I. M. & Green, W. R. Neurotoxic effects of cisplatin therapy. Arch. Neurol. 39, 719\u2013720 (1982).","journal-title":"Arch. Neurol."},{"key":"BFnrclinonc2015152_CR108","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/WCO.0b013e32832fbc52","volume":"22","author":"K Toyooka","year":"2009","unstructured":"Toyooka, K. & Fujimura, H. Iatrogenic neuropathies. Curr. Opin. Neurol. 22, 475\u2013479 (2009).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrclinonc2015152_CR109","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","volume":"40","author":"NC Miltenburg","year":"2014","unstructured":"Miltenburg, N. C. & Boogerd, W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat. Rev. 40, 872\u2013882 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrclinonc2015152_CR110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/EdBook_AM.2013.33.9","volume":"2013","author":"EL Mayer","year":"2013","unstructured":"Mayer, E. L. Early and late long-term effects of adjuvant chemotherapy. Am. Soc. Clin. Oncol. Educ. Book 2013, 9\u201314 (2013).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"BFnrclinonc2015152_CR111","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/bmj.300.6723.511","volume":"300","author":"SW Hansen","year":"1990","unstructured":"Hansen, S. W. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 300, 511\u2013512 (1990).","journal-title":"BMJ"},{"key":"BFnrclinonc2015152_CR112","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1002\/cncr.24384","volume":"115","author":"PA Cassier","year":"2009","unstructured":"Cassier, P. A. et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 115, 3392\u20133399 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR113","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","volume":"46","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti, G. et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur. J. Cancer 46, 479\u2013494 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2015152_CR114","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","volume":"6","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti, G. & Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity. Nat. Rev. Neurol. 6, 657\u2013666 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrclinonc2015152_CR115","doi-asserted-by":"publisher","first-page":"e68974","DOI":"10.1371\/journal.pone.0068974","volume":"8","author":"WW Chen","year":"2013","unstructured":"Chen, W. W., Wang, F. & Xu, R. H. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS ONE 8, e68974 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2015152_CR116","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0140-6736(05)78426-9","volume":"351","author":"AJ Dormann","year":"1998","unstructured":"Dormann, A. J., Grunewald, T., Wigginghaus, B. & Huchzermeyer, H. Gemcitabine-associated autonomic neuropathy. Lancet 351, 644 (1998).","journal-title":"Lancet"},{"key":"BFnrclinonc2015152_CR117","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0030-1255217","volume":"30","author":"EJ Dropcho","year":"2010","unstructured":"Dropcho, E. J. Neurotoxicity of cancer chemotherapy. Semin. Neurol. 30, 273\u2013286 (2010).","journal-title":"Semin. Neurol."},{"key":"BFnrclinonc2015152_CR118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0971-5851.96962","volume":"33","author":"K Gaurav","year":"2012","unstructured":"Gaurav, K., Goel, R. K., Shukla, M. & Pandey, M. Glutamine: a novel approach to chemotherapy-induced toxicity. Indian J. Med. Paediatr. Oncol. 33, 13\u201320 (2012).","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"BFnrclinonc2015152_CR119","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11912-009-0071-x","volume":"12","author":"P Giglio","year":"2010","unstructured":"Giglio, P. & Gilbert, M. R. Neurologic complications of cancer and its treatment. Curr. Oncol. Rep. 12, 50\u201359 (2010).","journal-title":"Curr. Oncol. Rep."},{"key":"BFnrclinonc2015152_CR120","first-page":"18","volume":"70","author":"AJ Beijers","year":"2012","unstructured":"Beijers, A. J., Jongen, J. L. & Vreugdenhil, G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth. J. Med. 70, 18\u201325 (2012).","journal-title":"Neth. J. Med."},{"key":"BFnrclinonc2015152_CR121","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi, C. L. et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J. Clin. Oncol. 32, 997\u20131005 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR122","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman, D. L. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 32, 1941\u20131967 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR123","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1345\/aph.1L179","volume":"42","author":"S Amara","year":"2008","unstructured":"Amara, S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann. Pharmacother. 42, 1481\u20131485 (2008).","journal-title":"Ann. Pharmacother."},{"key":"BFnrclinonc2015152_CR124","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf, B. et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313, 815\u2013823 (2015).","journal-title":"JAMA"},{"key":"BFnrclinonc2015152_CR125","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1254\/jphs.14058FP","volume":"125","author":"M Ohsawa","year":"2014","unstructured":"Ohsawa, M. et al. Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice. J. Pharmacol. Sci. 125, 292\u2013299 (2014).","journal-title":"J. Pharmacol. Sci."},{"key":"BFnrclinonc2015152_CR126","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4097\/kjae.2014.67.1.4","volume":"67","author":"HJ Park","year":"2014","unstructured":"Park, H. J. Chemotherapy induced peripheral neuropathic pain. Korean J. Anesthesiol. 67, 4\u20137 (2014).","journal-title":"Korean J. Anesthesiol."},{"key":"BFnrclinonc2015152_CR127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdiacomp.2014.08.008","volume":"29","author":"D Ziegler","year":"2015","unstructured":"Ziegler, D. & Fonseca, V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J. Diabetes Complications 29, 146\u2013156 (2015).","journal-title":"J. Diabetes Complications"},{"key":"BFnrclinonc2015152_CR128","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"A Badros","year":"2007","unstructured":"Badros, A. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110, 1042\u20131049 (2007).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR129","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24, 3113\u20133120 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR130","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jama.2013.7902","volume":"310","author":"M Seretny","year":"2013","unstructured":"Seretny, M., Colvin, L. & Fallon, M. Therapy for chemotherapy-induced peripheral neuropathy. JAMA 310, 537\u2013538 (2013).","journal-title":"JAMA"},{"key":"BFnrclinonc2015152_CR131","doi-asserted-by":"crossref","unstructured":"Martin, T. et al. Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial in patients with relapsed and refractory multiple myeloma (R\/R MM) [abstract]. ASH Annual Meeting Abstracts 116, a3031 (2010).","DOI":"10.1182\/blood.V116.21.3031.3031"},{"key":"BFnrclinonc2015152_CR132","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","volume":"24","author":"L Mileshkin","year":"2006","unstructured":"Mileshkin, L. et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J. Clin. Oncol. 24, 4507\u20134514 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR133","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.beha.2006.06.006","volume":"19","author":"A Mazumder","year":"2006","unstructured":"Mazumder, A. & Jagannath, S. Thalidomide and lenalidomide in multiple myeloma. Best Pract. Res. Clin. Haematol. 19, 769\u2013780 (2006).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"BFnrclinonc2015152_CR134","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/leu.2010.254","volume":"25","author":"KH Begna","year":"2011","unstructured":"Begna, K. H. et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25, 301\u2013304 (2011).","journal-title":"Leukemia"},{"key":"BFnrclinonc2015152_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11910-008-0039-5","volume":"8","author":"TN Kreisl","year":"2008","unstructured":"Kreisl, T. N. Neurologic complications of antitumor antibody therapies. Curr. Neurol. Neurosci. Rep. 8, 259\u2013263 (2008).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrclinonc2015152_CR136","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812\u20131821 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2015152_CR137","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/B978-0-7020-4088-7.00080-8","volume":"121","author":"R Soffietti","year":"2014","unstructured":"Soffietti, R., Trevisan, E. & Ruda, R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb. Clin. Neurol. 121, 1199\u20131218 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"BFnrclinonc2015152_CR138","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691\u20132697 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2015152_CR139","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1189::AID-CNCR27>3.0.CO;2-X","volume":"77","author":"VK Puduvalli","year":"1996","unstructured":"Puduvalli, V. K., Sella, A., Austin, S. G. & Forman, A. D. Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer 77, 1189\u20131192 (1996).","journal-title":"Cancer"},{"key":"BFnrclinonc2015152_CR140","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao, B., Shroff, S., Kamiya-Matsuoka, C. & Tummala, S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro. Oncol. 16, 589\u2013593 (2014).","journal-title":"Neuro. Oncol."},{"key":"BFnrclinonc2015152_CR141","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot, I., Blank, C. U., Boogerd, W. & Brandsma, D. Neurological immune-related adverse events of ipilimumab. Pract. Neurol. 13, 278\u2013280 (2013).","journal-title":"Pract. Neurol."},{"key":"BFnrclinonc2015152_CR142","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000112905","volume":"38","author":"I Bora","year":"1997","unstructured":"Bora, I. et al. Myasthenia gravis following IFN-\u03b1-2a treatment. Eur. Neurol. 38, 68 (1997).","journal-title":"Eur. Neurol."},{"key":"BFnrclinonc2015152_CR143","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00131402-200403000-00002","volume":"5","author":"J Srinivasan","year":"2004","unstructured":"Srinivasan, J., Wu, C. J. & Amato, A. A. Inflammatory myopathy associated with imatinib mesylate therapy. J. Clin. Neuromuscul. Dis. 5, 119\u2013121 (2004).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"BFnrclinonc2015152_CR144","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-011-0672-8","volume":"106","author":"E Pentsova","year":"2012","unstructured":"Pentsova, E. et al. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J. Neurooncol. 106, 15\u201321 (2012).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc2015152_CR145","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1212\/WNL.0b013e318271f87e","volume":"79","author":"X Chen","year":"2012","unstructured":"Chen, X., Schwartz, G. K., DeAngelis, L. M., Kaley, T. & Carvajal, R. D. Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology 79, 1929\u20131931 (2012).","journal-title":"Neurology"},{"key":"BFnrclinonc2015152_CR146","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/mus.20623","volume":"34","author":"J Rowin","year":"2006","unstructured":"Rowin, J., Cheng, G., Lewis, S. L. & Meriggioli, M. N. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve 34, 666\u2013669 (2006).","journal-title":"Muscle Nerve"},{"key":"BFnrclinonc2015152_CR147","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/brain\/119.5.1429","volume":"119","author":"J Bowen","year":"1996","unstructured":"Bowen, J., Gregory, R., Squier, M. & Donaghy, M. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain 119, 1429\u20131439 (1996).","journal-title":"Brain"},{"key":"BFnrclinonc2015152_CR148","doi-asserted-by":"publisher","first-page":"dju044","DOI":"10.1093\/jnci\/dju044","volume":"106","author":"LB Travis","year":"2014","unstructured":"Travis, L. B. et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J. Natl Cancer Inst. 106, dju044 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2015152_CR149","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s00520-006-0072-3","volume":"14","author":"AA Argyriou","year":"2006","unstructured":"Argyriou, A. A. et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support. Care Cancer 14, 1134\u20131140 (2006).","journal-title":"Support. Care Cancer"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:27:46Z","timestamp":1684452466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2015.152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFnrclinonc2015152"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2015.152","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]},"assertion":[{"value":"22 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}